静脉注射免疫球蛋白 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "静脉注射免疫球蛋白" in Chinese language version.

refsWebsite

Global rank Chinese rank

33web.archive.org

1^st place

25nih.gov

4^th place

5^th place

22doi.org

2^nd place

23^rd place

4archive.org

6^th place

4^th place

4semanticscholar.org

11^th place

332^nd place

3tga.gov.au

3,984^th place

1,603^rd place

3europa.eu

68^th place

209^th place

2hres.ca

low place

2canada.ca

1,712^th place

3,316^th place

2handle.net

102^nd place

492^nd place

2fda.gov

447^th place

581^st place

1drugs.com

399^th place

208^th place

1books.google.com

3^rd place

8^th place

1pcori.org

low place

1dynamed.com

low place

1mdanderson.org

low place

1primaryimmune.org

low place

1who.int

195^th place

179^th place

1plasvaccusa.com

low place

1aappublications.org

3,763^rd place

2,997^th place

1washingtonpost.com

34^th place

129^th place

1worldcat.org

5^th place

12^th place

1aaaai.org

low place

1igliving.com

low place

1transfusion.com.au

low place

1nytimes.com

7^th place

31^st place

1cbsnews.com

108^th place

449^th place

1genengnews.com

low place

1businesswire.com

615^th place

1,091^st place

1harvard.edu

18^th place

57^th place

aaaai.org

Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency (PDF). American Association of Allergists and Immunologists. [2015-11-23]. （原始内容存档 (PDF)于2016-03-05）.

aappublications.org

pediatrics.aappublications.org

Gern JE. Antiinflammatory Activity of IVIG Mediated through the Inhibitory FC Receptor. Pediatrics. August 2002, 110 (2): 467–8 [2012-05-28]. doi:10.1542/peds.110.2.S1.467-b. （原始内容存档于2008-06-11）.

archive.org

British national formulary : BNF 69 69. British Medical Association. 2015: 867–71. ISBN 9780857111562.
Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. August 2008, 48 (8): 1598–1601. PMID 18466176. S2CID 6010463. doi:10.1111/j.1537-2995.2008.01721.x.
Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. January 2007, 204 (1): 11–5. PMC 2118416 . PMID 17227911. doi:10.1084/jem.20061788.
Clynes R. Immune complexes as therapy for autoimmunity. J. Clin. Invest. January 2005, 115 (1): 25–7. PMC 539209 . PMID 15630438. doi:10.1172/JCI23994.

books.google.com

Etzioni A, Ochs HD. Primary Immunodeficiency Disorders: A Historic and Scientific Perspective. Academic Press. 2014: 283–84. ISBN 9780124115545. （原始内容存档于2017-01-09）（英语）.

businesswire.com

FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients. www.businesswire.com. 2020-05-20 [2020-05-28]. （原始内容存档于2020-06-21）（英语）.

canada.ca

Immune system health. Health Canada. 2018-05-09 [2024-04-13]. （原始内容存档于2022-01-19）.
Drug and medical device highlights 2018: Helping you maintain and improve your health. Health Canada. 2020 -10-14 [2024-04-17]. （原始内容存档于2024-04-17）. 请检查|date=中的日期值 (帮助)

cbsnews.com

Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests. CBS News. 2012-07-17 [2012-07-19]. （原始内容存档于2012-07-19）.

doi.org

Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. The Journal of Allergy and Clinical Immunology (Review). April 2006, 117 (4 Suppl): S525–S553. PMID 16580469. doi:10.1016/j.jaci.2006.01.015 .
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barré syndrome. Journal of Clinical Immunology. May 2010, 30 (S1): S74–S78. PMC 2883091 . PMID 20396937. doi:10.1007/s10875-010-9407-4.
Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. September 2003, 61 (6): 736–740. PMID 14504313. S2CID 20577426. doi:10.1212/WNL.61.6.736 .
Pondrom S. The IVIg dilemma. The AJT Report. American Journal of Transplantation. October 2014, 14 (10): 2195–2196. PMID 25231064. S2CID 221433035. doi:10.1111/ajt.12995 .
Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. August 2008, 48 (8): 1598–1601. PMID 18466176. S2CID 6010463. doi:10.1111/j.1537-2995.2008.01721.x.
Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF. Neonatal immune neutropenia following the administration of intravenous immune globulin. The American Journal of Pediatric Hematology/Oncology. February 1993, 15 (1): 120–123. PMID 8447553. doi:10.1097/00043426-199302000-00019.
Sugita K, Eguchi M. Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology. January 2005, 27 (1): 7–10. PMID 15654271. doi:10.1097/01.mph.0000149239.68396.72.
Stoevesandt J, Heitmann J, Goebeler M, Benoit S. [Not Available]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. December 2020, 18 (12): 1394–1404. PMID 33373142. doi:10.1111/ddg.14310_g .
Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Therapeutics and Clinical Risk Management. February 2010, 6: 1–10. PMC 2817783 . PMID 20169031. doi:10.2147/tcrm.s4353 .
Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD. Subcutaneous immunoglobulin: opportunities and outlook. Clinical and Experimental Immunology //www.ncbi.nlm.nih.gov/pmc/articles/PMC2801034 |PMC=缺少标题 (帮助). December 2009, 158 (Suppl 1): 51–59. PMC 2801034 . PMID 19883424. doi:10.1111/j.1365-2249.2009.04027.x .
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of Infectious Diseases. January 2015, 211 (1): 80–90. PMC 4264590 . PMID 25030060. doi:10.1093/infdis/jiu396.
Dias da Silva W, De Andrade SA, Megale ÂA, De Souza DA, Sant'Anna OA, Magnoli FC, Guidolin FR, Godoi KS, Saladini LY, Spencer PJ, Portaro FC. Antibodies as Snakebite Antivenoms: Past and Future. Toxins. September 2022, 14 (9): 606. PMC 9503307 . PMID 36136544. doi:10.3390/toxins14090606 .
Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. The Journal of Infectious Diseases. February 1999, 179 (Suppl 1): S218–S223. PMID 9988187. doi:10.1086/514294 .
Gern JE. Antiinflammatory Activity of IVIG Mediated through the Inhibitory FC Receptor. Pediatrics. August 2002, 110 (2): 467–8 [2012-05-28]. doi:10.1542/peds.110.2.S1.467-b. （原始内容存档于2008-06-11）.
Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. January 2007, 204 (1): 11–5. PMC 2118416 . PMID 17227911. doi:10.1084/jem.20061788.
Clynes R. Immune complexes as therapy for autoimmunity. J. Clin. Invest. January 2005, 115 (1): 25–7. PMC 539209 . PMID 15630438. doi:10.1172/JCI23994.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med. June 2006, 12 (6): 688–92. PMID 16715090. doi:10.1038/nm1416.
Bayry J, Thirion M, Misra N; et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol. Sci. October 2003,. 24 Suppl 4: S217–21. PMID 14598046. doi:10.1007/s10072-003-0081-7.
Janke AD, Yong VW. Impact of IVIg on the interaction between activated T cells and microglia. Neurol. Res. April 2006, 28 (3): 270–4. PMID 16687052. doi:10.1179/016164106X98143.
Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit. Care Med. December 2007, 35 (12): 2686–92. PMID 18074465. doi:10.1097/01.CCM.0000295312.13466.1C.
Boyer LV, Theodorou AA, Berg RA, Mallie J, Chávez-Méndez A, García-Ubbelohde W, Hardiman S, Alagón A. Antivenom for critically ill children with neurotoxicity from scorpion stings. The New England Journal of Medicine. May 2009, 360 (20): 2090–2098. PMID 19439743. doi:10.1056/NEJMoa0808455 .
Williams DJ, Habib AG, Warrell DA. Clinical studies of the effectiveness and safety of antivenoms. Toxicon. August 2018, 150: 1–10. Bibcode:2018Txcn..150....1W. PMID 29746978. S2CID 13665273. doi:10.1016/j.toxicon.2018.05.001.

drugs.com

Immune Globulin. The American Society of Health-System Pharmacists. [8 January 2017]. （原始内容存档于9 January 2017）.

dynamed.com

Immune Globulin. Dynamed. [2015-11-23]. （原始内容存档于2015-12-08）. Template:Subscription or libraries

europa.eu

ema.europa.eu

HyQvia EPAR. European Medicines Agency (EMA). 2013-06-03 [2020-07-14]. （原始内容存档于2020-07-15）.
Hizentra EPAR. European Medicines Agency (EMA). 2011-06-06 [2020-05-02]. （原始内容存档于2020-08-01）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

An EU-wide overview of the market of blood, blood components and plasma derivatives focusing on their availability for patients Creative Ceutical Report, revised by the Commission to include stakeholders' comments (PDF). Creative Ceutical & EU commission. [7 December 2015]. （原始内容存档 (PDF)于2015-12-22）.

fda.gov

Hizentra. U.S. Food and Drug Administration (FDA). 2018-03-15 [2020-05-03]. （原始内容存档于2020-04-01）.
Pierce LR. Summary Basis for Regulatory Action – Hizentra (PDF) (报告). Review Office Signatory Authority Tejashri Purohit-Sheth. U.S. Food and Drug Administration (FDA). 2018-03-14 [2018-03-20]. （原始内容存档 (PDF)于2018-03-20）.

genengnews.com

Another Alzheimer's Drug Fails Phase III Trial. （原始内容存档于2013-06-07）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.

harvard.edu

ui.adsabs.harvard.edu

Williams DJ, Habib AG, Warrell DA. Clinical studies of the effectiveness and safety of antivenoms. Toxicon. August 2018, 150: 1–10. Bibcode:2018Txcn..150....1W. PMID 29746978. S2CID 13665273. doi:10.1016/j.toxicon.2018.05.001.

hres.ca

hpr-rps.hres.ca

Regulatory Decision Summary - Xembify. Health Canada. 2014-10-23 [2022-06-07]. （原始内容存档于2022-06-07）.
Summary Basis of Decision - HyQvia. Health Canada. 2014-10-23 [2022-08-06]. （原始内容存档于2024-08-05）.

igliving.com

Berman K. SCIG: New Therapeutic Uses Beyond PI? (PDF). IG Living: 28–32. [2015-11-23]. （原始内容存档 (PDF)于2015-10-27）.

mdanderson.org

www3.mdanderson.org

Lichtiger B. Laboratory Serologic Problems Associated with Administration of Intravenous IgG. Current Issues in Transfusion Medicine (The University of Texas M. D. Anderson Cancer Center). April 1994, 3: 1–7 [2015-11-23]. （原始内容存档于5 March 2016）.

nih.gov

ncbi.nlm.nih.gov

Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. The Journal of Allergy and Clinical Immunology (Review). April 2006, 117 (4 Suppl): S525–S553. PMID 16580469. doi:10.1016/j.jaci.2006.01.015 .
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barré syndrome. Journal of Clinical Immunology. May 2010, 30 (S1): S74–S78. PMC 2883091 . PMID 20396937. doi:10.1007/s10875-010-9407-4.
Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. September 2003, 61 (6): 736–740. PMID 14504313. S2CID 20577426. doi:10.1212/WNL.61.6.736 .
Pondrom S. The IVIg dilemma. The AJT Report. American Journal of Transplantation. October 2014, 14 (10): 2195–2196. PMID 25231064. S2CID 221433035. doi:10.1111/ajt.12995 .
Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. August 2008, 48 (8): 1598–1601. PMID 18466176. S2CID 6010463. doi:10.1111/j.1537-2995.2008.01721.x.
Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF. Neonatal immune neutropenia following the administration of intravenous immune globulin. The American Journal of Pediatric Hematology/Oncology. February 1993, 15 (1): 120–123. PMID 8447553. doi:10.1097/00043426-199302000-00019.
Sugita K, Eguchi M. Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology. January 2005, 27 (1): 7–10. PMID 15654271. doi:10.1097/01.mph.0000149239.68396.72.
Stoevesandt J, Heitmann J, Goebeler M, Benoit S. [Not Available]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. December 2020, 18 (12): 1394–1404. PMID 33373142. doi:10.1111/ddg.14310_g .
Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Therapeutics and Clinical Risk Management. February 2010, 6: 1–10. PMC 2817783 . PMID 20169031. doi:10.2147/tcrm.s4353 .
Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD. Subcutaneous immunoglobulin: opportunities and outlook. Clinical and Experimental Immunology //www.ncbi.nlm.nih.gov/pmc/articles/PMC2801034 |PMC=缺少标题 (帮助). December 2009, 158 (Suppl 1): 51–59. PMC 2801034 . PMID 19883424. doi:10.1111/j.1365-2249.2009.04027.x .
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of Infectious Diseases. January 2015, 211 (1): 80–90. PMC 4264590 . PMID 25030060. doi:10.1093/infdis/jiu396.
Dias da Silva W, De Andrade SA, Megale ÂA, De Souza DA, Sant'Anna OA, Magnoli FC, Guidolin FR, Godoi KS, Saladini LY, Spencer PJ, Portaro FC. Antibodies as Snakebite Antivenoms: Past and Future. Toxins. September 2022, 14 (9): 606. PMC 9503307 . PMID 36136544. doi:10.3390/toxins14090606 .
Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. The Journal of Infectious Diseases. February 1999, 179 (Suppl 1): S218–S223. PMID 9988187. doi:10.1086/514294 .
Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. January 2007, 204 (1): 11–5. PMC 2118416 . PMID 17227911. doi:10.1084/jem.20061788.
Clynes R. Immune complexes as therapy for autoimmunity. J. Clin. Invest. January 2005, 115 (1): 25–7. PMC 539209 . PMID 15630438. doi:10.1172/JCI23994.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med. June 2006, 12 (6): 688–92. PMID 16715090. doi:10.1038/nm1416.
Bayry J, Thirion M, Misra N; et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol. Sci. October 2003,. 24 Suppl 4: S217–21. PMID 14598046. doi:10.1007/s10072-003-0081-7.
Janke AD, Yong VW. Impact of IVIg on the interaction between activated T cells and microglia. Neurol. Res. April 2006, 28 (3): 270–4. PMID 16687052. doi:10.1179/016164106X98143.
Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit. Care Med. December 2007, 35 (12): 2686–92. PMID 18074465. doi:10.1097/01.CCM.0000295312.13466.1C.
Boyer LV, Theodorou AA, Berg RA, Mallie J, Chávez-Méndez A, García-Ubbelohde W, Hardiman S, Alagón A. Antivenom for critically ill children with neurotoxicity from scorpion stings. The New England Journal of Medicine. May 2009, 360 (20): 2090–2098. PMID 19439743. doi:10.1056/NEJMoa0808455 .
Williams DJ, Habib AG, Warrell DA. Clinical studies of the effectiveness and safety of antivenoms. Toxicon. August 2018, 150: 1–10. Bibcode:2018Txcn..150....1W. PMID 29746978. S2CID 13665273. doi:10.1016/j.toxicon.2018.05.001.

dailymed.nlm.nih.gov

Asceniv – human immunoglobulin g liquid. DailyMed. [2021-06-09]. （原始内容存档于2021-06-09）.
Bivigam (immune globulin intravenous – human 10% liquid. DailyMed. [2021-06-09]. （原始内容存档于2021-06-09）.
Gamunex-C (immune globulin – human injection. DailyMed. [2021-06-09]. （原始内容存档于2021-06-09）.
Alyglo- human immunoglobulin g liquid. DailyMed. 15 December 2023 [2024-03-03]. （原始内容存档于2024-03-03）.

nytimes.com

Andrew Pollack. Small Trial Hints Drug Can Slow Alzheimer's. New York Times. 2012-07-17 [2012-07-19]. （原始内容存档于2012-07-19）.

pcori.org

Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians | PCORI. www.pcori.org. 2024-05-09 [2024-07-11]. （原始内容存档于2024-06-30）（英语）.

plasvaccusa.com

What is Hyperimmunized Plasma?. Plasvacc USA. 2021-05-20 [2023-05-23]. （原始内容存档于2023-03-27）（美国英语）.

primaryimmune.org

Powell L. Re: A Message from CSL Behring to Current Vivaglobin Patients in the United States (PDF). Primary Immune Foundation. [24 November 2015]. （原始内容存档 (PDF)于2015-12-22）.

semanticscholar.org

api.semanticscholar.org

Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. September 2003, 61 (6): 736–740. PMID 14504313. S2CID 20577426. doi:10.1212/WNL.61.6.736 .
Pondrom S. The IVIg dilemma. The AJT Report. American Journal of Transplantation. October 2014, 14 (10): 2195–2196. PMID 25231064. S2CID 221433035. doi:10.1111/ajt.12995 .
Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. August 2008, 48 (8): 1598–1601. PMID 18466176. S2CID 6010463. doi:10.1111/j.1537-2995.2008.01721.x.
Williams DJ, Habib AG, Warrell DA. Clinical studies of the effectiveness and safety of antivenoms. Toxicon. August 2018, 150: 1–10. Bibcode:2018Txcn..150....1W. PMID 29746978. S2CID 13665273. doi:10.1016/j.toxicon.2018.05.001.

tga.gov.au

Xembify APMDS. Therapeutic Goods Administration (TGA). 2022-07-15 [2022-07-17]. （原始内容存档于2022-07-14）.
Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.
Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.

transfusion.com.au

transfusion.com.au. transfusion.com.au. [2019-11-14]. （原始内容存档于2019-09-04）（英语）.

washingtonpost.com

Ingraham C. The crazy reason it costs $14,000 to treat a snakebite with $14 medicine. Washington Post. 2021-11-25 [2023-05-23]. ISSN 0190-8286. （原始内容存档于2023-07-02）（美国英语）.

web.archive.org

Xembify APMDS. Therapeutic Goods Administration (TGA). 2022-07-15 [2022-07-17]. （原始内容存档于2022-07-14）.
Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.
Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.
Regulatory Decision Summary - Xembify. Health Canada. 2014-10-23 [2022-06-07]. （原始内容存档于2022-06-07）.
Summary Basis of Decision - HyQvia. Health Canada. 2014-10-23 [2022-08-06]. （原始内容存档于2024-08-05）.
Immune system health. Health Canada. 2018-05-09 [2024-04-13]. （原始内容存档于2022-01-19）.
Drug and medical device highlights 2018: Helping you maintain and improve your health. Health Canada. 2020 -10-14 [2024-04-17]. （原始内容存档于2024-04-17）. 请检查|date=中的日期值 (帮助)
Asceniv – human immunoglobulin g liquid. DailyMed. [2021-06-09]. （原始内容存档于2021-06-09）.
Bivigam (immune globulin intravenous – human 10% liquid. DailyMed. [2021-06-09]. （原始内容存档于2021-06-09）.
Gamunex-C (immune globulin – human injection. DailyMed. [2021-06-09]. （原始内容存档于2021-06-09）.
Alyglo- human immunoglobulin g liquid. DailyMed. 15 December 2023 [2024-03-03]. （原始内容存档于2024-03-03）.
HyQvia EPAR. European Medicines Agency (EMA). 2013-06-03 [2020-07-14]. （原始内容存档于2020-07-15）.
Immune Globulin. The American Society of Health-System Pharmacists. [8 January 2017]. （原始内容存档于9 January 2017）.
Etzioni A, Ochs HD. Primary Immunodeficiency Disorders: A Historic and Scientific Perspective. Academic Press. 2014: 283–84. ISBN 9780124115545. （原始内容存档于2017-01-09）（英语）.
Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians | PCORI. www.pcori.org. 2024-05-09 [2024-07-11]. （原始内容存档于2024-06-30）（英语）.
Immune Globulin. Dynamed. [2015-11-23]. （原始内容存档于2015-12-08）. Template:Subscription or libraries
Lichtiger B. Laboratory Serologic Problems Associated with Administration of Intravenous IgG. Current Issues in Transfusion Medicine (The University of Texas M. D. Anderson Cancer Center). April 1994, 3: 1–7 [2015-11-23]. （原始内容存档于5 March 2016）.
Powell L. Re: A Message from CSL Behring to Current Vivaglobin Patients in the United States (PDF). Primary Immune Foundation. [24 November 2015]. （原始内容存档 (PDF)于2015-12-22）.
Antivenoms. www.who.int. [2023-05-23]. （原始内容存档于2023-05-07）（英语）.
What is Hyperimmunized Plasma?. Plasvacc USA. 2021-05-20 [2023-05-23]. （原始内容存档于2023-03-27）（美国英语）.
Gern JE. Antiinflammatory Activity of IVIG Mediated through the Inhibitory FC Receptor. Pediatrics. August 2002, 110 (2): 467–8 [2012-05-28]. doi:10.1542/peds.110.2.S1.467-b. （原始内容存档于2008-06-11）.
Ingraham C. The crazy reason it costs $14,000 to treat a snakebite with $14 medicine. Washington Post. 2021-11-25 [2023-05-23]. ISSN 0190-8286. （原始内容存档于2023-07-02）（美国英语）.
Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency (PDF). American Association of Allergists and Immunologists. [2015-11-23]. （原始内容存档 (PDF)于2016-03-05）.
Hizentra EPAR. European Medicines Agency (EMA). 2011-06-06 [2020-05-02]. （原始内容存档于2020-08-01）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Hizentra. U.S. Food and Drug Administration (FDA). 2018-03-15 [2020-05-03]. （原始内容存档于2020-04-01）.
Pierce LR. Summary Basis for Regulatory Action – Hizentra (PDF) (报告). Review Office Signatory Authority Tejashri Purohit-Sheth. U.S. Food and Drug Administration (FDA). 2018-03-14 [2018-03-20]. （原始内容存档 (PDF)于2018-03-20）.
Berman K. SCIG: New Therapeutic Uses Beyond PI? (PDF). IG Living: 28–32. [2015-11-23]. （原始内容存档 (PDF)于2015-10-27）.
An EU-wide overview of the market of blood, blood components and plasma derivatives focusing on their availability for patients Creative Ceutical Report, revised by the Commission to include stakeholders' comments (PDF). Creative Ceutical & EU commission. [7 December 2015]. （原始内容存档 (PDF)于2015-12-22）.
transfusion.com.au. transfusion.com.au. [2019-11-14]. （原始内容存档于2019-09-04）（英语）.
Andrew Pollack. Small Trial Hints Drug Can Slow Alzheimer's. New York Times. 2012-07-17 [2012-07-19]. （原始内容存档于2012-07-19）.
Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests. CBS News. 2012-07-17 [2012-07-19]. （原始内容存档于2012-07-19）.
Another Alzheimer's Drug Fails Phase III Trial. （原始内容存档于2013-06-07）.
FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients. www.businesswire.com. 2020-05-20 [2020-05-28]. （原始内容存档于2020-06-21）（英语）.

who.int

Antivenoms. www.who.int. [2023-05-23]. （原始内容存档于2023-05-07）（英语）.

worldcat.org

Ingraham C. The crazy reason it costs $14,000 to treat a snakebite with $14 medicine. Washington Post. 2021-11-25 [2023-05-23]. ISSN 0190-8286. （原始内容存档于2023-07-02）（美国英语）.